	US 12,390,517 B2
	Compositions, methods and uses for eliciting an immune response
Freda E.-C. Jen, Nathan (AU); Kate Seib, Nathan (AU); Evgeny Semchenko, Nathan (AU); and Michael Jennings, Nathan (AU)
Assigned to GRIFFITH UNIVERSITY, Nathan (AU)
Appl. No. 17/416,271
Filed by Griffith University, Nathan (AU)
PCT Filed Dec. 20, 2019, PCT No. PCT/AU2019/051418 § 371(c)(1), (2) Date Jun. 18, 2021, PCT Pub. No. WO2020/124159, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 2018904887 (AU), filed on Dec. 21, 2018.
Prior Publication US 2022/0062402 A1, Mar. 3, 2022
Int. Cl. A61K 39/095 (2006.01); A61K 39/00 (2006.01); C12N 15/86 (2006.01)

CPC A61K 39/095 (2013.01) [C12N 15/86 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/70 (2013.01)]

27 Claims

1. A method for eliciting an immune response to N. gonorrhoeae or N. meningitidis in a subject, comprising administering to the subject a composition, comprising:

a recombinant or synthetic methionine sulfoxide reductase A/B (MsrA/B) polypeptide, or a recombinant or synthetic polynucleotide encoding the MsrA/B polypeptide, and an adjuvant; or

a viral vector comprising a polynucleotide encoding the MsrA/B polypeptide;

wherein the MsrA/B polypeptide:

(a) lacks 1 to 16 amino acids from the N-terminus of a full-length MsrA/B polypeptide, wherein the full-length MsrA/B polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1 or an amino acid sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO:1; or

(b) is an antigenic fragment of a polypeptide defined in (a), wherein the antigenic fragment is at least 30 amino acids long.